Research demonstrates the link between plasma P-tau217 and cognitive decline in Lewy body disorders, indicating its potential as a biomarker.
Plasma P-tau217 detects Alzheimer's disease co-pathology in Lewy body disorders and predicts cognitive decline. Future studies will evaluate associations between plasma P-tau217 and imaging and clinical outcomes, in consideration for use of amyloid-targeting therapies in Lewy body disorders. ANN NEUROL 2026.
No takes yet. Share an insight, caveat, or question.
Tropea et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: